IL-17 Is a Key Regulator of Mucin-Galectin-3 Interactions in Asthma

Mucus hypersecretion and chronic airway inflammation are standard characteristics of several airway diseases, such as chronic obstructive pulmonary disease and asthma. Increased mucus secretion from increased mucin gene expression in the airway epithelium is associated with poor prognosis and mortality. We previously showed that the absence of tissue inhibitor of metalloproteinase 1 (TIMP-1) enhances lung inflammation, airway hyperreactivity, and lung remodeling in asthma in an ovalbumin (OVA) asthma model of TIMP-1 knockout (TIMPKO) mice as compared to wild-type (WT) controls and mediated by increased galectin-3 (Gal-3) levels. Additionally, we have shown that in the lung epithelial cell line A549, Gal-3 inhibition increases interleukin-17 (IL-17) levels, leading to increased mucin expression in the airway epithelium. Therefore, in the current study, we further examined the relationship between Gal-3 and the production of IL-17-axis cytokines and critical members of the mucin family in the murine TIMPKO asthma model and the lung epithelium cell line A549. While Gal-3 may regulate a Th1/Th2 response, IL-17 could stimulate the mucin genes, MUC5B and MUC5AC. Gal-3 and IL-17 interactions induce mucus expression in OVA-sensitized mice. We conclude that Gal-3 may play an essential role in the pathogenesis of asthma, and modulation of Gal-3 may prove helpful in the treatment of this disease.

 

Comments:

It seems like you've provided a detailed summary of a research study that investigates the role of galectin-3 (Gal-3) in the context of airway diseases, particularly asthma, with a focus on mucus hypersecretion and chronic airway inflammation. Here's a breakdown of the key findings and conclusions from your provided text:

1. **Background**: Mucus hypersecretion and chronic airway inflammation are common features of airway diseases such as chronic obstructive pulmonary disease (COPD) and asthma. Increased mucus production, driven by elevated mucin gene expression in airway epithelial cells, is associated with poor prognosis and increased mortality in these diseases.

2. **Previous Research**: The study builds upon previous research that demonstrated the absence of tissue inhibitor of metalloproteinase 1 (TIMP-1) leads to enhanced lung inflammation, airway hyperreactivity, and lung remodeling in an ovalbumin (OVA) asthma model using TIMP-1 knockout (TIMP KO) mice compared to wild-type (WT) controls. This effect is mediated by increased levels of galectin-3 (Gal-3).

3. **Role of Gal-3**: Gal-3 is implicated as a key factor in regulating the pathogenesis of asthma. Gal-3 inhibition was found to increase interleukin-17 (IL-17) levels in the lung epithelial cell line A549. This increase in IL-17 contributes to elevated mucin expression in the airway epithelium.

4. **Study Objectives**: The current study aimed to explore the relationship between Gal-3 and the production of IL-17-related cytokines and mucin genes in both the TIMP KO asthma model and the A549 lung epithelial cell line.

5. **Th1/Th2 Response**: While Gal-3 may have a role in regulating the balance between Th1 and Th2 immune responses, the study suggests that IL-17, a cytokine associated with inflammation, may stimulate the expression of mucin genes MUC5B and MUC5AC.

6. **Gal-3 and IL-17 Interaction**: The interaction between Gal-3 and IL-17 appears to induce mucus expression in OVA-sensitized mice, contributing to the airway pathology seen in asthma.

7. **Conclusion**: The study concludes that Gal-3 likely plays a significant role in the pathogenesis of asthma. Modulation of Gal-3 activity may hold promise as a therapeutic approach for the treatment of asthma, possibly by mitigating mucus hypersecretion and airway inflammation.

In summary, this research suggests that Gal-3 is a potential target for asthma treatment due to its involvement in regulating inflammation and mucin gene expression in the airways, both of which are key factors in the disease's pathogenesis. Further research in this area may lead to the development of novel therapies for asthma.

Related Products

Cat.No.	Product Name	Information
S1451	TCS7010 (Aurora A Inhibitor I)	TCS7010 (Aurora A Inhibitor I) is a novel, potent, and selective inhibitor of Aurora A with IC50 of 3.4 nM in a cell-free assay. It is 1000-fold more selective for Aurora A than Aurora B. Aurora A Inhibitor I (TC-S 7010) triggers apoptosis through the ROS-mediated UPR signaling pathway.

Related Targets

Apoptosis related Aurora Kinase